This startup is developing an AI model using living skin that remains viable for a month.

      Outer Biosciences has emerged from a four-year stealth phase, having successfully kept surgically discarded human skin alive for up to a month while feeding the findings into an AI model that predicts beneficial compounds. The company has raised approximately $23 million and employs 19 staff members.

      Based in Massachusetts, this company has dedicated four years to maintaining human skin outside the body. Outer Biosciences claims it can keep surgically discarded tissue viable for up to one month, conducting experiments during this time without public disclosure.

      The purpose of this tissue is to inform a model. An AI system predicts which untested chemicals could affect specific skin functions; the living tissue tests these predictions, and the results—whether accurate or not—are fed back into the model.

      The pace of progress increased once this feedback loop was established. Initial work utilizing scientific literature produced a few leads in about 18 months, whereas the company now reports generating a candidate approximately every six weeks.

      The tissue is sourced from surgeries, primarily cosmetic in nature. Outer obtains it through biobanks and brokers operating under institutional review board supervision and documented donor consent, ensuring that identifiers are removed before the tissue is received. The company states it pays fees on a cost-recovery basis rather than purchasing the tissue outright.

      The technical emphasis is on duration rather than innovation. Living tissue is generally viable for only a few days, adequate for acute toxicity testing but insufficient for assessing processes like collagen remodeling, pigmentation change, and barrier repair, which require weeks to occur.

      Outer asserts that a sample that is a month old still bears resemblance to a sample from day one, albeit not identical. This statement is carefully moderated by the company.

      Commerce in this field sidesteps medical applications entirely. The company focuses on discovering cosmetic ingredients rather than pharmaceuticals, which means there is no need for regulatory approval; only a standardized industry designation and safety testing under OECD guidelines accepted by member countries are required.

      This is particularly relevant in Europe. Over a decade ago, the EU prohibited animal testing for cosmetics, making validated alternative methods a necessity rather than merely an ethical choice.

      Since then, the EU has advanced significantly. On June 1, the European Commission adopted a roadmap to phase out animal testing in chemical safety assessments, featuring over 30 recommendations in a marketplace where AI biology is evolving faster than the surrounding validation systems.

      Europe has framed the demand, while America is working on the supply. Outer is not the only player in this arena; Vivodyne has raised nearly $80 million for lab-grown human tissue, and various organ-on-chip companies are pursuing the same preclinical market.

      What Outer identifies as its competitive advantage is decidedly grounded and tangible. There is no biology internet from which to extract data; its data is uniquely sourced, and it operates its models on its own machines to keep this data off the cloud, a different approach compared to many other AI firms.